On November 8, 2024, Merck announced that Canada's Drug Agency (CDA) recommended WINREVAIR (sotatercept) for reimbursement. This recommendation is for its use in combination with standard pulmonary arterial hypertension (PAH) therapy for adults with WHO Group 1 PAH and Functional Class II or III.
This marks a significant step towards broader market access for Winrevair in Canada. The next phase involves negotiations with Merck Canada for public funding by participating drug plans.
Winrevair is the first activin signaling inhibitor therapy for PAH in Canada, and its recommendation for reimbursement is a positive development for patients and for Merck's cardiovascular portfolio. It has been eight years since a new pharmacological therapy for PAH was launched in Canada.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.